HK Stock Movement | LUYE PHARMA (02186) Rises Over 3% as New Drug LY03017 Approved for Clinical Trials in the U.S. Targeting PDP and Other Conditions

Stock News11-26

LUYE PHARMA (02186) surged more than 3%, reaching HK$3.2 by the time of writing, with a trading volume of HK$28.32 million. On November 24, the company announced that its self-developed novel drug LY03017, a next-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials. LY03017 is intended for treating Alzheimer’s disease psychosis (ADP), Parkinson’s disease psychosis (PDP), and negative symptoms of schizophrenia (NSS). The FDA has waived the single ascending dose (SAD) phase in the Phase I trial, allowing the drug to proceed directly to multiple ascending dose (MAD) and subsequent clinical trials. Developed under the company’s new molecular entity/therapeutic entity platform, LY03017 represents another innovative drug in the central nervous system (CNS) therapeutic area being developed simultaneously in China and the U.S. Currently, LY03017 is also in Phase I clinical trials in China. Globally, only one drug has been approved by the FDA for PDP treatment, and it has not yet been approved in China. For ADP, no drugs have been approved domestically or internationally, while for NSS, only a few drugs show limited efficacy. These three indications represent significant unmet medical needs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment